Nothing Special   »   [go: up one dir, main page]

MX9701183A - Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones. - Google Patents

Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.

Info

Publication number
MX9701183A
MX9701183A MX9701183A MX9701183A MX9701183A MX 9701183 A MX9701183 A MX 9701183A MX 9701183 A MX9701183 A MX 9701183A MX 9701183 A MX9701183 A MX 9701183A MX 9701183 A MX9701183 A MX 9701183A
Authority
MX
Mexico
Prior art keywords
steps
preparing
applications
influenza virus
influenzal
Prior art date
Application number
MX9701183A
Other languages
English (en)
Inventor
Jean-Michel Violay
Guy Court
Catherine Gerdil
Herve Chalumeau
Patrick Verry
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of MX9701183A publication Critical patent/MX9701183A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161Methods of inactivation or attenuation
    • C12N2760/16163Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procedimiento de preparacion de antígenos gripales purificados, a partir de un líquido que contiene el virus gripal, que comprende las etapas de concentracion de purificacion, de fragmentacion y eventualmente de inactivacion caracterizado porque: A. o bien la etapa de purificacion comprende varias etapas de ultracentrifugacion separadas por una etapa de filtracion, B. o bien la etapa de fragmentacion no ionico anfífilo seguido de una eliminacion de substancias indeseables por filtracion que retiene el conjunto de constituyentes virales, o bien se opera de acuerdo a estas dos etapas en cualquier orden.
MX9701183A 1994-08-16 1995-06-06 Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones. MX9701183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9410039A FR2723740B1 (fr) 1994-08-16 1994-08-16 Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
PCT/FR1995/000727 WO1996005294A1 (fr) 1994-08-16 1995-06-06 Procede de preparation du virus grippal, antigens obtenus et leurs applications

Publications (1)

Publication Number Publication Date
MX9701183A true MX9701183A (es) 1997-05-31

Family

ID=9466323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701183A MX9701183A (es) 1994-08-16 1995-06-06 Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.

Country Status (10)

Country Link
US (1) US6048537A (es)
EP (1) EP0776362A1 (es)
JP (1) JPH10504033A (es)
AU (1) AU701024B2 (es)
CA (1) CA2197683C (es)
FR (1) FR2723740B1 (es)
MX (1) MX9701183A (es)
NZ (1) NZ288254A (es)
WO (1) WO1996005294A1 (es)
ZA (1) ZA956797B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938767C2 (de) * 1999-08-16 2002-10-24 Tad Pharma Gmbh Spaltimpfstoffe
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
KR100473070B1 (ko) * 2002-08-31 2005-03-10 박승국 시각적 유도장치를 이용한 외국어 학습 및 교습 시스템
US7270990B2 (en) * 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
RU2006145303A (ru) * 2004-05-20 2008-06-27 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН (CA) Способ получения противогриппозной вакцины
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
DE06808434T1 (de) * 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen phasen tensid als adjuvans für spalt-grippeimpfstoffe
WO2007096418A1 (en) * 2006-02-23 2007-08-30 Ovagen International Limited Improved methods of producing avian eggs and birds of specified germ-free status
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2008135230A1 (en) * 2007-05-04 2008-11-13 Baxter International Inc. Two-step temperature profile for the propagation of viruses
ES2459166T3 (es) * 2007-08-28 2014-05-08 Baxter International Inc. Procedimiento para la producción de vacunas víricas
TW200936758A (en) * 2007-11-02 2009-09-01 Intervet Int Bv Orthomyxoviridae propagation
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
ES2615390T3 (es) * 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
JP5843615B2 (ja) 2009-02-06 2016-01-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製
CN103764160A (zh) * 2009-05-29 2014-04-30 诺华有限公司 流感病毒血凝素试验
CN107213461B (zh) 2009-09-10 2022-03-15 勃林格殷格翰动物保健美国公司 包含含有皂苷的佐剂的新疫苗制剂
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2013025274A1 (en) 2011-08-12 2013-02-21 Merial Limited Vacuum -assisted preservation of biological products, in particular of vaccines
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
TWI745278B (zh) 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
JP7018941B2 (ja) 2016-06-17 2022-02-14 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 直鎖または分枝ポリアクリル酸ポリマーアジュバントを含む新規な免疫原性処方物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4000257A (en) * 1975-12-22 1976-12-28 American Cyanamid Company Process for the purification of influenza virus vaccine
US4057626A (en) * 1976-10-08 1977-11-08 Richardson-Merrell Inc. Process for detoxifying influenza B virus
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
FR2483779A1 (fr) * 1980-06-05 1981-12-11 Synthelabo Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins
US4327182A (en) * 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.

Also Published As

Publication number Publication date
FR2723740A1 (fr) 1996-02-23
WO1996005294A1 (fr) 1996-02-22
CA2197683A1 (en) 1996-02-22
US6048537A (en) 2000-04-11
AU2741295A (en) 1996-03-07
FR2723740B1 (fr) 1996-11-08
NZ288254A (en) 1999-01-28
JPH10504033A (ja) 1998-04-14
ZA956797B (en) 1997-02-17
EP0776362A1 (fr) 1997-06-04
CA2197683C (en) 2008-12-30
AU701024B2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
TW346398B (en) System and methods for removing viral agents from blood
AU580402B2 (en) Method of inactivating viruses involving adsorption on solid phase
KR860008276A (ko) 단백질이 생성된 배양기로 부터 그것을 추출, 정제하는 방법
TR199901840T2 (xx) DNA'nın cross-flow-filtrasyonu ile temizlenmesi.
ATE189697T1 (de) Die hocheffiziente herstellung und isolierung von viruspartikeln
ATE324436T1 (de) Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
FI99192B (fi) Menetelmä virusten inaktivoimiseksi veressä ja verituotteissa
DE60132094D1 (de) Verfahren zur Herstellung von gereinigten Partikeln
AU4058595A (en) Process and apparatus for removal of DNA, viruses and endotoxins
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE283277T1 (de) Verfahren zur entfernung von viren aus proteinlösungen mittels nanofiltration
DK0646594T3 (da) Fremgangsmåde til rensning af proteiner
EA199800685A1 (ru) Разделение компонентов плазмы крови с помощью фильтрующих средств на основе целлюлозы
AU747417C (en) Filtration method for separating viruses
ES2193210T3 (es) Separacion de virus de soluciones de proteinas por ultrafiltracion.
DE69833256D1 (de) Methode zur entfernung von endotoxinen aus impstoffen
HUP0301211A2 (hu) Vérzéscsillapító hatású vWF-tartalmú készítmény és eljárás annak előállítására
DE69940338D1 (de) Vereinfachte methode zur entfernung von freiem protein während der herstellung von protein-polysaccharid-konjugaten und impfstoffen unter verwendung von medien mit limitierter durchlässigkeit
ES2196870T3 (es) Procedimiento para la purificacion o aislamiento de acidos nucleicos virales.
ES2099678B1 (es) Procedimiento para la inactivacion de virus en proteinas.
AU640841B2 (en) Process for the purification of white phosphorus
ES2169040T3 (es) Planta resistente a dos o mas virus y preparacion de la misma.
ATE132160T1 (de) Verfahren zur reinigung von aussenmembran-protein von haemophilus influenza
GR930100408A (el) Μέ?οδος απομόνωσης και κα?αρισμού μεβινολίνης.